Amesite Announces 69% QoQ Revenue Increase in Q2 2026 and Product Plans for Coming Months

Rhea-AI Summary

Amesite (NASDAQ: AMST) reported a 69% quarter-over-quarter revenue increase in Q2 2026 while reducing spending and expanding customers in post-acute healthcare. The company cited 82% and 69% QoQ revenue gains across the last two quarters, rising customer adoption of its NurseMagic™ AI platform, and high engagement with 6,500 daily explainer-video views and 28,000 daily website visitors. Amesite plans to launch what it describes as the first AI-powered EMR for post-acute care by 2026 and emphasized continued AI-driven product rollouts and operational discipline.

Positive

• Revenue +69% QoQ in Q2 2026
• Revenue +82% QoQ in the prior quarter
• 6,500 average daily explainer-video views
• 28,000 average daily website visitors
• Planned launch of AI-powered EMR for post-acute care by 2026

Negative

• None.

Insights

Financial Strategist

Strong quarter with material QoQ revenue growth and cost control; operational discipline cited as driver.

Amesite reports a 69% quarter‑over‑quarter revenue increase and says it reduced spending while expanding customer adoption in post‑acute healthcare. The combination of revenue acceleration and lower operating expenses suggests improving unit economics and better cash flow dynamics, based solely on the disclosed figures.

Key dependencies include sustaining revenue momentum and converting increased web engagement into contracted, recurring revenue; both are cited but not quantified beyond the 69% figure and web traffic metrics. Watch upcoming quarterly reports for retention, recurring revenue breakdowns, and explicit operating expense trends over the next several quarters.

Product and Healthcare Technology Analyst

Product roadmap targets an AI‑powered EMR for post‑acute care by 2026, which if delivered would be strategically notable.

The company highlights rapid deployment of its NurseMagic™ AI stack and plans to launch an AI‑powered EMR platform aimed at post‑acute providers. This describes a clear product focus on operational efficiency in a defined segment and signals potential differentiation through AI integration, per the disclosure.

Risks and dependencies are delivery and regulatory or integration hurdles, none of which are quantified here; the statement is a plan, not a performance metric. Monitor concrete milestones: product beta availability, customer contracts for the EMR, and any published performance or pilot results within the next 12 months.

Shareholder Update Reports Positive Customer Reviews, New Segment Growth and Technology Rollouts across Post-Acute Healthcare

DETROIT, Oct. 30, 2025 (GLOBE NEWSWIRE) -- Amesite Inc. (NASDAQ: AMST), a leading developer of AI-powered enterprise solutions, announces a 69% QoQ increase in revenue even as it reduced its spending. Amesite also reported expanding its customer base and offerings to post-acute health businesses across the U.S. The Company described these results and its pathway to offer the first AI-powered electronic medical record (EMR) by 2026 in a shareholder update made available yesterday on its website. As part of the shareholder update, Amesite Founder & CEO, Dr. Ann Marie Sastry discussed:

• Summary of FY 2025 10-K and Q1 2026 10-Q: Financial performance was described in the context of methodical execution of platform capabilities demanded by customers.
• Excellent Product Reviews: Customer feedback was described, underscoring high satisfaction and increased adoption in post-acute healthcare segments.
• Efficient Technology Innovation: Rapid deployment of Amesite's proprietary AI technology was described, crediting the AI-forward infrastructure used at the inception of the NurseMagic^TM product family.
• Upcoming Product Plans: Amesite announced the planned launch of what it believes is the industry’s first AI-powered EMR platform for post-acute care, aiming to deliver operational efficiency for the fastest-growing healthcare segments.
  
  

“Our team’s focus on operational discipline has enabled us to drive revenue growth while reducing operating expenses,” said Madison Bush, Director of Corporate Operations. “We are focused on delivering increased value to our shareholders by practicing what we preach: using AI-powered process optimization that continuously increases our business efficiency. Importantly, our customer engagement has accelerated since Q12026, with an average of 6,500 daily views of our platform explainer video and 28,000 daily website visitors.”

“Our increased revenue, of 82% and 69% QoQ for the last two quarters, reflects the strong demand from our customers for NurseMagic^TM’s AI-powered platform support,” added Brandon Owens, VP of Sales. “With a strong technology foundation, and relationships built through delivery of value, we believe that we will grow our business with existing customers and also onboard new, larger clients because of our differentiation in technology.”

“The only way to solve the urgent need to increase the efficiency of delivery of U.S. healthcare, while also improving the quality of care, is through innovation. AI will play the most important role in this transition. By methodically rolling out capabilities and services on our proprietary, AI-powered NurseMagic^TM platform, we are working to meet the strong demand for end-to-end, AI-enhanced platform support for post-acute care,” said Dr. Ann Marie Sastry, Founder & CEO.

About Amesite Inc.

Amesite (NASDAQ: AMST) is an AI-driven company with an immediate aim to transform the $330 billion home and healthcare segments. Its flagship product, NurseMagic™, streamlines healthcare documentation, reducing the time required from 20 minutes to just 20 seconds. NurseMagic™ is used by over 100 professions to improve care, enhance operational efficiency and improve financial performance. Built on proprietary AI trained on industry-specific data, NurseMagic meets HIPAA regulations while improving accuracy and efficiency. The platform serves B2B and B2C users across 50 states and 21 countries, offering seamless integration into healthcare workflows and translations to over 50 languages.

Forward-Looking Statements

This communication contains forward-looking statements (including within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and Section 27A of the Securities Act of 1933, as amended) concerning the Company, the Company's planned online machine learning platform, the Company's business plans, any future commercialization of the Company's online learning solutions, potential customers, business objectives and other matters. Forward-looking statements generally include statements that are predictive in nature and depend upon or refer to future events or conditions, and include words such as "may," "will," "should," "would," "expect," "plan," "believe," "intend," "look forward," and other similar expressions among others. Statements that are not historical facts are forward-looking statements. Forward-looking statements are based on current beliefs and assumptions that are subject to risks and uncertainties and are not guarantees of future performance. Actual results could differ materially from those contained in any forward-looking statement. Risks facing the Company and its planned platform are set forth in the Company's filings with the SEC. Except as required by applicable law, the Company undertakes no obligation to revise or update any forward-looking statement, or to make any other forward-looking statements, whether as a result of new information, future events or otherwise.

Investor Relations

ir@amesite.com

FAQ

What revenue change did Amesite (AMST) report for Q2 2026?

Amesite reported a 69% quarter-over-quarter revenue increase in Q2 2026.

What are Amesite's (AMST) recent customer engagement metrics reported Oct 30, 2025?

The company reported an average of 6,500 daily explainer-video views and 28,000 daily website visitors.

When does Amesite (AMST) plan to launch its AI-powered EMR for post-acute care?

Amesite announced plans to launch what it believes is the first AI-powered EMR for post-acute care by 2026.

How has Amesite (AMST) described its spending and operations alongside revenue growth?

The company said it reduced spending while driving revenue growth through operational discipline and AI process optimization.

What recent revenue trend did Amesite (AMST) highlight across the last two quarters?

Amesite cited sequential revenue gains of 82% and 69% QoQ over the last two reported quarters.